Ivan Panajotovich Kodonidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ivan Panajotovich Kodonidi has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Alexey S. Chiriapkin
Пятигорский медико-фармацевтический институт — филиал ВолгГМУ
16 shared publications - Alexander A. Glushko
Volgograd State Medical University
6 shared publications - Dmitryi Igorevich Pozdnyakov
Pyatigorsk Medical and Pharmaceutical Institute, Branch of the Volgograd State Medical University
6 shared publications - Alexander V. Ivchenko
Pyatigorsk Medical and Pharmaceutical Institute – a branch of Volgograd State Medical University
4 shared publications - Denis Stanislavovich Anenko
Pyatigorsk Medical Pharmaceutical Institute – branch of Volgograd State Medical University
4 shared publications - Oleg Ivanovich Kit
National Medical Research Centre for Oncology, Rostov-on-Don, Russia
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2630
Antitumor and Antimetastatic Activity of a Novel Pyrimidin-4-one Derivative in the B16–F10 Melanoma Mouse Model: A Pilot Study
Введение. Меланома кожи характеризуется высоким метастатическим потенциалом. Участие EGFR в инвазии и прогрессировании меланомы обосновывает поиск новых EGFR-ориентированных антиметастатических подходов. Цель. Оценка влияния нового производного пиримидин-4-она (6MPSVan-Na) на рост, метастазирование и морфологию перевивной меланомы В16-F10. Материалы и методы. Эксперимент выполнен на самцах мышей C57BL/6 с подкожно трансплантированной меланомой В16–F10. Животные были распределены на три группы (по n = 10 в каждой): основная группа (6MPSVan-Na, 18,7 мг/кг внутримышечно); отрицательный контроль (вода для инъекций внутримышечно); группа гефитиниба (43,4 мг/кг перорально) как позитивный контроль чувствительности модели к ингибиторам тирозинкиназы EGFR. Воздействие проводили в течение пяти дней со дня перевивки, через два дня курс повторяли. Оценивали латентный период, динамику объема и торможения роста опухоли (ТРО %), продолжительность жизни, выживаемость (Kаплан — Майер), частоту макрометастазов. Проведен гистологический анализ опухолевой ткани. Статистическая обработка: критерии Манна — Уитни, точный критерий Фишера, log-rank-тест, ANOVA (уровень значимости α = 0,05). Результаты. Исследование выявило чувствительность меланомы В16-F10 к действию референтного препарат гефитиниба. Профиль противоопухолевой активности экспериментального соединения 6MPSVan-Na характеризовался торможением роста меланомы в постэкспозиционный период (ТРО % ≥ 50 %), статистически значимым увеличением продолжительности жизни мышей, снижением частоты выявления макрометастазов в легких до 20 %, в лимфоузлах — до 30 % (p < 0,05). После воздействия 6MPSVan-Na преимущественно определялись морфологические признаки некроптоза (обширный некроз, выраженная инфильтрация лимфоцитами и гистиоцитами, формирование лимфоцитарного вала и соединительнотканной капсулы). Заключение. В пилотном исследовании новое производное пиримидин-4-она продемонстрировало противоопухолевую и антиметастатическую активность в отношении меланомы В16-F10, реализующуюся, вероятно, через активацию некроптоза и стимуляцию опухолеспецифического иммунного ответа. Полученные данные обосновывают дальнейшее изучение 6MPSVan-Na в качестве потенциального антиметастатического агента при меланоме.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2630
Open AccessAntitumor and Antimetastatic Activity of a Novel Pyrimidin-4-one Derivative in the B16–F10 Melanoma Mouse Model: A Pilot Study
Введение. Меланома кожи характеризуется высоким метастатическим потенциалом. Участие EGFR в инвазии и прогрессировании меланомы обосновывает поиск новых EGFR-ориентированных антиметастатических подходов. Цель. Оценка влияния нового производного пиримидин-4-она (6MPSVan-Na) на рост, метастазирование и морфологию перевивной меланомы В16-F10. Материалы и методы. Эксперимент выполнен на самцах мышей C57BL/6 с подкожно трансплантированной меланомой В16–F10. Животные были распределены на три группы (по n = 10 в каждой): основная группа (6MPSVan-Na, 18,7 мг/кг внутримышечно); отрицательный контроль (вода для инъекций внутримышечно); группа гефитиниба (43,4 мг/кг перорально) как позитивный контроль чувствительности модели к ингибиторам тирозинкиназы EGFR. Воздействие проводили в течение пяти дней со дня перевивки, через два дня курс повторяли. Оценивали латентный период, динамику объема и торможения роста опухоли (ТРО %), продолжительность жизни, выживаемость (Kаплан — Майер), частоту макрометастазов. Проведен гистологический анализ опухолевой ткани. Статистическая обработка: критерии Манна — Уитни, точный критерий Фишера, log-rank-тест, ANOVA (уровень значимости α = 0,05). Результаты. Исследование выявило чувствительность меланомы В16-F10 к действию референтного препарат гефитиниба. Профиль противоопухолевой активности экспериментального соединения 6MPSVan-Na характеризовался торможением роста меланомы в постэкспозиционный период (ТРО % ≥ 50 %), статистически значимым увеличением продолжительности жизни мышей, снижением частоты выявления макрометастазов в легких до 20 %, в лимфоузлах — до 30 % (p < 0,05). После воздействия 6MPSVan-Na преимущественно определялись морфологические признаки некроптоза (обширный некроз, выраженная инфильтрация лимфоцитами и гистиоцитами, формирование лимфоцитарного вала и соединительнотканной капсулы). Заключение. В пилотном исследовании новое производное пиримидин-4-она продемонстрировало противоопухолевую и антиметастатическую активность в отношении меланомы В16-F10, реализующуюся, вероятно, через активацию некроптоза и стимуляцию опухолеспецифического иммунного ответа. Полученные данные обосновывают дальнейшее изучение 6MPSVan-Na в качестве потенциального антиметастатического агента при меланоме.
- 29 April 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (2)
Prediction, in silico antioxidant activity, and targeted synthesis of sterically hindered phenol azomethine derivatives
Molecular design and synthesis of a new series of biologically active azomethines containing a sterically hindered phenolic fragment were carried out. Within the scope of the study, 8 compounds were synthesized, and their antioxidant activity was evaluated under in vitro conditions. To establish the mechanism of action, molecular docking was used to model the interaction of the synthesized ligands with the active site of glutathione peroxidase-4 (GPx-4). The conducted analysis revealed key structural features determining antioxidant efficacy and established a correlation between molecular structure and biological activity. The aim . Synthesis, computer screening, and investigation of the antioxidant properties of new azomethines based on sterically hindered phenol, as well as establishing structure–activity relationships. Materials and methods . A new series of 2,6-di-tert-butyl-4-[C-alkyl-(aryl)-(N-phenyl)-azomethine]phenols was synthesized by the condensation of corresponding ketones with aromatic amines in the presence of catalytic amounts of p-toluenesulfonic acid. The structure and purity of the obtained compounds were confirmed by a complex of physicochemical methods, including IR spectroscopy, H NMR spectroscopy, and elemental analysis. For the initial assessment of the biological potency of the synthesized compounds, computer prediction ( in silico ) of their antioxidant, antiradical, and cardiotonic properties was performed using the online platform PASS Online. Molecular modeling of potential inhibitory activity against human glutathione peroxidase-4 (GPx-4) was carried out using the Autodock 4.0 program. The conformational mobility of the ligands was taken into account, for which optimal torsion angles were previously determined and set. Experimental study of antioxidant activity (AOA) was conducted in two model systems: induction of lipid peroxidation (LPO) in a complex of corn oil fatty acids under UV irradiation; and the Fenton system (H₂O₂/Fe²⁺). To compare efficacy, ubiquinone and bottled hydroxytoluene (BHT, the active substance of the drug dibulin), representing the class of sterically hindered phenols, were used as reference standards. Results . The spectrum of biological activity of the studied compounds was predicted in silico using the PASS Online service. As it was expected, all substances have cardiotonic, membrane-stimulating, and antioxidant potential. The presence of AOA and the ability to scavenge free radicals allows these molecules to be classified as antiradical agents. Experimental verification of AOA was carried out in two model systems: based on photooxidation (UV irradiation) of a complex of fatty acids from corn oil (system No. 1) and on the Fenton system (H₂O₂/Fe²⁺, system No. 2). In all the cases, the studied compounds demonstrated high efficacy, inhibiting lipid peroxidation LPO by 42–48%. This result significantly exceeds the activity of standard antioxidants — ubiquinone (11%) and BHT (39%) — in the same conditions. Conclusion . The results of molecular docking indicate a high affinity of the new ligands to the GP-4 protein, with the calculated binding energy for the most promising structures being comparable to that of known standards—ubiquinone, dibulin (hydroxybutylated toluene), and mexidol. In vitro experimental data confirmed the pronounced antioxidant activity of the synthesized compounds. “Lead” structures were identified that surpass classical antioxidants—ubiquinone and dibulin — in efficacy.
- 29 April 2026
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 14 (2)
Prediction, in silico antioxidant activity, and targeted synthesis of sterically hindered phenol azomethine derivatives
Molecular design and synthesis of a new series of biologically active azomethines containing a sterically hindered phenolic fragment were carried out. Within the scope of the study, 8 compounds were synthesized, and their antioxidant activity was evaluated under in vitro conditions. To establish the mechanism of action, molecular docking was used to model the interaction of the synthesized ligands with the active site of glutathione peroxidase-4 (GPx-4). The conducted analysis revealed key structural features determining antioxidant efficacy and established a correlation between molecular structure and biological activity. The aim . Synthesis, computer screening, and investigation of the antioxidant properties of new azomethines based on sterically hindered phenol, as well as establishing structure–activity relationships. Materials and methods . A new series of 2,6-di-tert-butyl-4-[C-alkyl-(aryl)-(N-phenyl)-azomethine]phenols was synthesized by the condensation of corresponding ketones with aromatic amines in the presence of catalytic amounts of p-toluenesulfonic acid. The structure and purity of the obtained compounds were confirmed by a complex of physicochemical methods, including IR spectroscopy, H NMR spectroscopy, and elemental analysis. For the initial assessment of the biological potency of the synthesized compounds, computer prediction ( in silico ) of their antioxidant, antiradical, and cardiotonic properties was performed using the online platform PASS Online. Molecular modeling of potential inhibitory activity against human glutathione peroxidase-4 (GPx-4) was carried out using the Autodock 4.0 program. The conformational mobility of the ligands was taken into account, for which optimal torsion angles were previously determined and set. Experimental study of antioxidant activity (AOA) was conducted in two model systems: induction of lipid peroxidation (LPO) in a complex of corn oil fatty acids under UV irradiation; and the Fenton system (H₂O₂/Fe²⁺). To compare efficacy, ubiquinone and bottled hydroxytoluene (BHT, the active substance of the drug dibulin), representing the class of sterically hindered phenols, were used as reference standards. Results . The spectrum of biological activity of the studied compounds was predicted in silico using the PASS Online service. As it was expected, all substances have cardiotonic, membrane-stimulating, and antioxidant potential. The presence of AOA and the ability to scavenge free radicals allows these molecules to be classified as antiradical agents. Experimental verification of AOA was carried out in two model systems: based on photooxidation (UV irradiation) of a complex of fatty acids from corn oil (system No. 1) and on the Fenton system (H₂O₂/Fe²⁺, system No. 2). In all the cases, the studied compounds demonstrated high efficacy, inhibiting lipid peroxidation LPO by 42–48%. This result significantly exceeds the activity of standard antioxidants — ubiquinone (11%) and BHT (39%) — in the same conditions. Conclusion . The results of molecular docking indicate a high affinity of the new ligands to the GP-4 protein, with the calculated binding energy for the most promising structures being comparable to that of known standards—ubiquinone, dibulin (hydroxybutylated toluene), and mexidol. In vitro experimental data confirmed the pronounced antioxidant activity of the synthesized compounds. “Lead” structures were identified that surpass classical antioxidants—ubiquinone and dibulin — in efficacy.
- 14 January 2026
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (12) , 12-18
Синтез производных пиримидин-4(1H)-она, o-бензоиламинобензойной кислоты с остатком ГАМК, обладающих влиянием на мозговой кровоток и сердечно-сосудистую систему
Эффективным подходом в молекулярном конструировании фармакологических веществ с церебропротекторной и кардиотропной активностью является использование скаффолдов, близких по строению к эндогенным соединениям и содержащих фрагменты тормозных нейромедиаторов. Предполагается создание инновационных субстанций, способствующих улучшению мозгового кровообращения. В данной работе целенаправленно синтезированы производные пиримидин-4(1H)-она, o-бензоиламинобензойной кислоты, содержащие остаток ГАМК — соответственно 4-(2,6-диметил-5-фенил-4-оксо-пиримидин-1-ил)бутановая кислота (PDMGB) и 4-[(2-бензамидобензоил)амино]бутановая кислота (NcQGB). Представлены результаты квантово-химического расчета механизма циклоконденсации ядра пиримидинона, а также модификация синтеза производного o-бензоиламинобензойной кислоты. Проведен анализ влияния новых соединений на изменение объемной скорости мозгового кровотока и на некоторые параметры деятельности сердечно-сосудистой системы у крыс.
- 14 January 2026
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (12) , 12-18
Синтез производных пиримидин-4(1H)-она, o-бензоиламинобензойной кислоты с остатком ГАМК, обладающих влиянием на мозговой кровоток и сердечно-сосудистую систему
Эффективным подходом в молекулярном конструировании фармакологических веществ с церебропротекторной и кардиотропной активностью является использование скаффолдов, близких по строению к эндогенным соединениям и содержащих фрагменты тормозных нейромедиаторов. Предполагается создание инновационных субстанций, способствующих улучшению мозгового кровообращения. В данной работе целенаправленно синтезированы производные пиримидин-4(1H)-она, o-бензоиламинобензойной кислоты, содержащие остаток ГАМК — соответственно 4-(2,6-диметил-5-фенил-4-оксо-пиримидин-1-ил)бутановая кислота (PDMGB) и 4-[(2-бензамидобензоил)амино]бутановая кислота (NcQGB). Представлены результаты квантово-химического расчета механизма циклоконденсации ядра пиримидинона, а также модификация синтеза производного o-бензоиламинобензойной кислоты. Проведен анализ влияния новых соединений на изменение объемной скорости мозгового кровотока и на некоторые параметры деятельности сердечно-сосудистой системы у крыс.
- Open Access
- 1 January 2025
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №5 2025,p. 3
EXPERIMENTAL EVALUTION OF ANTITUMOR EFFICACY OF NOVEL DOMESTIC EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKERS INHIBITORS
- 1 January 2025
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №5 2025,p. 3
Open AccessEXPERIMENTAL EVALUTION OF ANTITUMOR EFFICACY OF NOVEL DOMESTIC EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKERS INHIBITORS
- Open Access
- 1 January 2025
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №3 2025,p. 68
ANTITUMOR ACTIVITY OF A NOVEL PYRIMIDIN-4(1H)-ONE DERIVATIVE IN NON-SMALL CELL LUNG CANCER MODELS IN VITRO
- 1 January 2025
- Published by Euroasian Scientific and Industrial Chamber, Ltd. in Современные проблемы науки и образования (Modern Problems of Science and Education)
- No. №3 2025,p. 68
Open AccessANTITUMOR ACTIVITY OF A NOVEL PYRIMIDIN-4(1H)-ONE DERIVATIVE IN NON-SMALL CELL LUNG CANCER MODELS IN VITRO
- Open Access
- 15 September 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (3) , 54-64
Antitumor effect of a new human epidermal growth factor receptor inhibitor
Purpose of the study. Preclinical study in experiment of antitumor efficacy of a new substance synthesized on the basis of pyrimidin-4-one derivative. Materials and methods. The sodium salt of 4-{2-[2-[2-(4-hydroxy-3-methoxyphenyl)-vinyl]-6-ethyl-4-oxo-5-phenyl-4H-pyrimidin-1-yl}-benzsulfamide, a new inhibitor of the internal domain of the epidermal growth factor receptor (EGFR), was used in this study. All C57BL6 mice of both sexes were subcutaneously transplanted with B16/F10 melanoma. Twenty-four hours after tumor transplantation, mice in the main group (n = 18) were injected with a new EGFR inhibitor intramuscularly at a dose of 0.375 mg per mouse (15,0 mg/kg animal masses), while mice in the control group (n = 18) were injected with saline for injection. In both groups administration was carried out before natural death of animals according to the scheme: administration daily for 5 days, followed by 2 days of break. The dynamics of animal weight, dynamics of tumor node volume were evaluated, the tumor growth inhibition index (TGII) was calculated. Results. Tumor visualization time and animal weight did not statistically significantly differ between the groups during the whole study. In the main group there was a longer lifespan by 1.5 times on average (p ≤ 0.05), and smaller average tumor volume (by 19.2 times on 14 days in males, by 4.3 times in females, by 4.3 times on 28 days in males, by 2.5 times in females, p ≤ 0.05) than in the control group. At the same time, in the main group the tumor volume was smaller in males by 2.7 and 1.8 times (p ≤ 0.05), respectively on days 25 and 28 than in females. TGII in mice of both sexes was maximal on the 14th day with subsequent decrease by 40.3 % in females and only by 18.6 % in males, and during the whole experiment TGII in males was higher. Conclusion. The results showed inhibition of melanoma growth and increased lifespan of mice of both sexes (more pronounced in males) in the group with administration of a new EGFR inhibitor. This indicates the promising potential of this compound and the need to continue its preclinical study in other tumor models.
- 15 September 2024
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 11 (3) , 54-64
Open AccessAntitumor effect of a new human epidermal growth factor receptor inhibitor
Purpose of the study. Preclinical study in experiment of antitumor efficacy of a new substance synthesized on the basis of pyrimidin-4-one derivative. Materials and methods. The sodium salt of 4-{2-[2-[2-(4-hydroxy-3-methoxyphenyl)-vinyl]-6-ethyl-4-oxo-5-phenyl-4H-pyrimidin-1-yl}-benzsulfamide, a new inhibitor of the internal domain of the epidermal growth factor receptor (EGFR), was used in this study. All C57BL6 mice of both sexes were subcutaneously transplanted with B16/F10 melanoma. Twenty-four hours after tumor transplantation, mice in the main group (n = 18) were injected with a new EGFR inhibitor intramuscularly at a dose of 0.375 mg per mouse (15,0 mg/kg animal masses), while mice in the control group (n = 18) were injected with saline for injection. In both groups administration was carried out before natural death of animals according to the scheme: administration daily for 5 days, followed by 2 days of break. The dynamics of animal weight, dynamics of tumor node volume were evaluated, the tumor growth inhibition index (TGII) was calculated. Results. Tumor visualization time and animal weight did not statistically significantly differ between the groups during the whole study. In the main group there was a longer lifespan by 1.5 times on average (p ≤ 0.05), and smaller average tumor volume (by 19.2 times on 14 days in males, by 4.3 times in females, by 4.3 times on 28 days in males, by 2.5 times in females, p ≤ 0.05) than in the control group. At the same time, in the main group the tumor volume was smaller in males by 2.7 and 1.8 times (p ≤ 0.05), respectively on days 25 and 28 than in females. TGII in mice of both sexes was maximal on the 14th day with subsequent decrease by 40.3 % in females and only by 18.6 % in males, and during the whole experiment TGII in males was higher. Conclusion. The results showed inhibition of melanoma growth and increased lifespan of mice of both sexes (more pronounced in males) in the group with administration of a new EGFR inhibitor. This indicates the promising potential of this compound and the need to continue its preclinical study in other tumor models.
- Open Access
- 28 May 2024
- Published by Voronezh State University in Сорбционные и хроматографические процессы
- Vol. 24 (2) , 257-267
Изучение стабильности биологически активного соединения N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина с использованием электрофореза и масс-спектрометрии
На базе центра инновационных отечественных лекарственных препаратов «Волгоградского государственного медицинского университета» сконструирован и синтезирован ряд пиримидиновых производных гуанидина для исследования их в качестве перспективных ингибиторов натрий-водородного обмена типа 1 (NHE-1), которые полезны для снижения поражения ткани при ишемии. Наиболее фармакологически ценным соединением оказался N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина (VMA-13-15). При создании нормативной документации для нового лекарственного средства одним из критериев качества является показатель «Родственные примеси», которыми могут быть технологические примеси и продукты деструкции действующего вещества. Целью исследования является изучение стабильности биологически активного соединения N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина. Определение предполагаемых продуктов деградации проводили методом стрессовых испытаний, используя методы капиллярного электрофореза и масс-спектроскопии. Изучение молекулы исследуемого VMA-13-15 и использование компьютерных технологий позволили спрогнозировать возможные процессы деструкции, среди которых наиболее вероятной может быть реакция гидролиза при термостатировании раствора исследуемого соединения в щелочной среде. In silico оптимизация геометрии рассматриваемых структур проводилась с использованием метода молекулярной механики ММ+ в программе HyperChem 8.0.9. Итоговая пространственная оптимизация геометрии моделируемых молекул осуществлялась методом теории функционала плотности ub3lyp с базисным набором 6-311G**. Результирующий колебательный анализ термодинамических характеристик проводился в программе Orca, которая позволила получить значения энтальпий и энтропий для изучаемых соединений. Методом капиллярного электрофореза проведен анализ продуктов деградации водного раствора исследуемого вещества посредством «стресс-тестов», которыми изучалось влияния термического воздействия на VMA-13-15 в присутствии 0.1М раствора кислоты хлористоводородной и 0.1М раствора натрия гидроксида. Установлено, что наибольшее влияние на стабильность N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина оказывает щелочная среда, что и следовало из результатов вычислительного эксперимента. Изучен масс-спектр обнаруженного при термостатировании в щелочной среде продукта деградации. По совпадению молярной массы и времени выхода было подтверждено, что примесь на хроматограммах VMA-13-15 является незамещенным хиназолин-4(3H)-оном – исходным продуктом синтеза.
- 28 May 2024
- Published by Voronezh State University in Сорбционные и хроматографические процессы
- Vol. 24 (2) , 257-267
Open AccessИзучение стабильности биологически активного соединения N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина с использованием электрофореза и масс-спектрометрии
На базе центра инновационных отечественных лекарственных препаратов «Волгоградского государственного медицинского университета» сконструирован и синтезирован ряд пиримидиновых производных гуанидина для исследования их в качестве перспективных ингибиторов натрий-водородного обмена типа 1 (NHE-1), которые полезны для снижения поражения ткани при ишемии. Наиболее фармакологически ценным соединением оказался N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина (VMA-13-15). При создании нормативной документации для нового лекарственного средства одним из критериев качества является показатель «Родственные примеси», которыми могут быть технологические примеси и продукты деструкции действующего вещества. Целью исследования является изучение стабильности биологически активного соединения N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина. Определение предполагаемых продуктов деградации проводили методом стрессовых испытаний, используя методы капиллярного электрофореза и масс-спектроскопии. Изучение молекулы исследуемого VMA-13-15 и использование компьютерных технологий позволили спрогнозировать возможные процессы деструкции, среди которых наиболее вероятной может быть реакция гидролиза при термостатировании раствора исследуемого соединения в щелочной среде. In silico оптимизация геометрии рассматриваемых структур проводилась с использованием метода молекулярной механики ММ+ в программе HyperChem 8.0.9. Итоговая пространственная оптимизация геометрии моделируемых молекул осуществлялась методом теории функционала плотности ub3lyp с базисным набором 6-311G**. Результирующий колебательный анализ термодинамических характеристик проводился в программе Orca, которая позволила получить значения энтальпий и энтропий для изучаемых соединений. Методом капиллярного электрофореза проведен анализ продуктов деградации водного раствора исследуемого вещества посредством «стресс-тестов», которыми изучалось влияния термического воздействия на VMA-13-15 в присутствии 0.1М раствора кислоты хлористоводородной и 0.1М раствора натрия гидроксида. Установлено, что наибольшее влияние на стабильность N-[2-[4-оксо-3(4Н)-хиназолинил]пропионил]-гуанидина оказывает щелочная среда, что и следовало из результатов вычислительного эксперимента. Изучен масс-спектр обнаруженного при термостатировании в щелочной среде продукта деградации. По совпадению молярной массы и времени выхода было подтверждено, что примесь на хроматограммах VMA-13-15 является незамещенным хиназолин-4(3H)-оном – исходным продуктом синтеза.
- Open Access
- 30 April 2024
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 10 (2) , 15-33
Chemical Composition And Biological Activity Of Secondary Metabolites From Cuscuta Campestris
The review summarizes the literature data on the chemical composition and types of biological activity of extracts of Cuscuta campestris Yunck (field dodder), which belongs to the Convolvulaceae family. C. campestris is an aboveground parasite. Its stems wrap around the host plants and are attached to them by gaustoria, which are formed in places of contact with the feeding plant and deeply embedded in its tissue. On the territory of the Russian Federation, there are more than 30 types of dodders. Extracts of C. campestris are used in traditional medicine in South Asia, but the plant is not used as an object of biologically active compounds in Russia. It is worth noting that in recent years, studies of the pharmacological properties of C. campestris have intensified, which made it possible to establish the presence of a wide range of biological activity in the plant. For instance, the cures of field dodder exert anti-inflammatory, tranquilizing, antitumor, antipyretic, antioxidant, cerebroprotective, antifungal, antiviral, analgesic, and hepatoprotective effects. In the case of isolation of the major components of C. campestris extracts, it seemed possible to assume the importance of certain substances in the realization of their pharmacological activity, which is discussed in this review. Sugars and sugar acids, sex pheromones, tannins, carotenoids, amino acids, fatty acids and their esters, polyphenols (including flavonoids), coumarins, triterpenoids, vitamins, furans, pyrans and lactones were identified among the secondary metabolites. Due to the fact that the plant in question is widely represented on the territory of the Russian Federation and it is affordable, C. campestris is a promising object of research for the creation of new effective medicines based on it.
- 30 April 2024
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 10 (2) , 15-33
Open AccessChemical Composition And Biological Activity Of Secondary Metabolites From Cuscuta Campestris
The review summarizes the literature data on the chemical composition and types of biological activity of extracts of Cuscuta campestris Yunck (field dodder), which belongs to the Convolvulaceae family. C. campestris is an aboveground parasite. Its stems wrap around the host plants and are attached to them by gaustoria, which are formed in places of contact with the feeding plant and deeply embedded in its tissue. On the territory of the Russian Federation, there are more than 30 types of dodders. Extracts of C. campestris are used in traditional medicine in South Asia, but the plant is not used as an object of biologically active compounds in Russia. It is worth noting that in recent years, studies of the pharmacological properties of C. campestris have intensified, which made it possible to establish the presence of a wide range of biological activity in the plant. For instance, the cures of field dodder exert anti-inflammatory, tranquilizing, antitumor, antipyretic, antioxidant, cerebroprotective, antifungal, antiviral, analgesic, and hepatoprotective effects. In the case of isolation of the major components of C. campestris extracts, it seemed possible to assume the importance of certain substances in the realization of their pharmacological activity, which is discussed in this review. Sugars and sugar acids, sex pheromones, tannins, carotenoids, amino acids, fatty acids and their esters, polyphenols (including flavonoids), coumarins, triterpenoids, vitamins, furans, pyrans and lactones were identified among the secondary metabolites. Due to the fact that the plant in question is widely represented on the territory of the Russian Federation and it is affordable, C. campestris is a promising object of research for the creation of new effective medicines based on it.
- 31 January 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
USE OF UV SPECTROPHOTOMETRY IN ANALYSIS AND STANDARDIZATION OF 2-BENZOYLAMINO-N- [4- (4,6-DIMETHYLPYRIMIDIN-2-ILSULFAMOYL) -PHENYL] -BENZAMIDE SUBSTANCE
Borderline neuropsychiatric disorders firmly hold a leading position in a large group of mental illnesses, among which neuroses occupy a significant place. The increasing number of patients with diseases associated with neuropsychiatric disorders makes the search and introduction of highly effective anxiolytics and antidepressants into medical practice increasingly important. In parallel with the search for medicinal substances with such pharmacological properties, it is necessary to resolve issues of standardization and quality control. One of these drugs may be a new synthetic derivative of ortho-benzoylaminobenzoic acid, which has antidepressant and anxiolytic effects. This compound was synthesized at the department of organic chemistry of the Pyatigorsk Medical and Pharmaceutical Institute under the leadership of professor Kodonidi I.P. Several biologically active compounds were synthesized - derivatives of o-benzoylaminobenzoic acid, one of which is 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide (laboratory code - PMFI-195) . Preliminary pharmacological studies of PMFI-195, carried out on the basis of the Federal State Budgetary Educational Institution of Higher Education of the Stavropol State Medical University of the Ministry of Health of Russia and the Federal State Budgetary Educational Institution of Higher Education of the North Caucasus Federal University, under the leadership of professor Manvelyan E.A., showed the promise of developing a drug based on the substance PMFI-195 for the treatment of such diseases such as depression, neuroses, psychopathy, neurosis-like and psycho-like states. Quality control and development of modern methods of pharmaceutical analysis is one of the basic stages of introducing pharmaceutical substances into production. This requires an in-depth study of physicochemical characteristics, as well as the selection and justification of methods of analysis and quality control of pharmaceuticals. substances. The results of the developed method for the qualitative determination by UV spectrophotometric method of a new quinosalinone derivative 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide, which has anxiolytic and antidepressant activity, are presented.
- 31 January 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
USE OF UV SPECTROPHOTOMETRY IN ANALYSIS AND STANDARDIZATION OF 2-BENZOYLAMINO-N- [4- (4,6-DIMETHYLPYRIMIDIN-2-ILSULFAMOYL) -PHENYL] -BENZAMIDE SUBSTANCE
Borderline neuropsychiatric disorders firmly hold a leading position in a large group of mental illnesses, among which neuroses occupy a significant place. The increasing number of patients with diseases associated with neuropsychiatric disorders makes the search and introduction of highly effective anxiolytics and antidepressants into medical practice increasingly important. In parallel with the search for medicinal substances with such pharmacological properties, it is necessary to resolve issues of standardization and quality control. One of these drugs may be a new synthetic derivative of ortho-benzoylaminobenzoic acid, which has antidepressant and anxiolytic effects. This compound was synthesized at the department of organic chemistry of the Pyatigorsk Medical and Pharmaceutical Institute under the leadership of professor Kodonidi I.P. Several biologically active compounds were synthesized - derivatives of o-benzoylaminobenzoic acid, one of which is 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide (laboratory code - PMFI-195) . Preliminary pharmacological studies of PMFI-195, carried out on the basis of the Federal State Budgetary Educational Institution of Higher Education of the Stavropol State Medical University of the Ministry of Health of Russia and the Federal State Budgetary Educational Institution of Higher Education of the North Caucasus Federal University, under the leadership of professor Manvelyan E.A., showed the promise of developing a drug based on the substance PMFI-195 for the treatment of such diseases such as depression, neuroses, psychopathy, neurosis-like and psycho-like states. Quality control and development of modern methods of pharmaceutical analysis is one of the basic stages of introducing pharmaceutical substances into production. This requires an in-depth study of physicochemical characteristics, as well as the selection and justification of methods of analysis and quality control of pharmaceuticals. substances. The results of the developed method for the qualitative determination by UV spectrophotometric method of a new quinosalinone derivative 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide, which has anxiolytic and antidepressant activity, are presented.
- 15 January 2024
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 57 (8) , 1189-1196
Targeted Synthesis of New 5-Phenyl-2-[(E)-Styryl]-1H-Pyrimidin-6-One Derivatives and Their Inhibitory Activity Toward SARS-CoV-2 Major (MPRO) and Papain-Like Proteases (PLPRO)
- 15 January 2024
- Published by Springer Nature in Pharmaceutical Chemistry Journal
- Vol. 57 (8) , 1189-1196
Targeted Synthesis of New 5-Phenyl-2-[(E)-Styryl]-1H-Pyrimidin-6-One Derivatives and Their Inhibitory Activity Toward SARS-CoV-2 Major (MPRO) and Papain-Like Proteases (PLPRO)